Key result
Regional statin guidelines for older adults diverge by interpreting trial evidence as protocol versus principle.
Answers are grounded in this paper and cite their sources.
Demonstrates how healthcare payers navigate clinical trial uncertainty for statin guidelines in the elderly, highlighting reliance on physiological principles and moral values.
This article explores some implications of the increasing reliance on clinical trials in contemporary health care, particularly health care payers’ efforts to use them in the so-called fourth hurdle decisions. How do these agencies manage medical uncertainty given the desire to produce clear guidelines for clinicians? Their solutions take account of trials in at least two ways, reflecting broader debates about the meaning of these medical experiments. Trials can be read as either ‘‘proofs of protocol’’—straightforward guides to action with individual drugs in specific populations—or ‘‘proofs of principle’’— where extrapolation is made possible through an appeal to underlying biological mechanisms. These contrasting readings of trials are illustrated with reference to guidelines on heart disease prevention/cholesterol reduction using statins among the elderly in North America and the United Kingdom. Uncertainty in these cases does not lead to inertia but solutions use different fixed points to aid navigation, including both physiological principles and moral values.
No takes yet. Share an insight, caveat, or question.
Catherine Will (2009) conducted a review in Heart disease prevention / cholesterol reduction. Statins was evaluated. Statin guidelines for the elderly in North America and the UK interpret clinical trials as either proofs of protocol or proofs of principle to manage medical uncertainty.
Synapse has enriched 10 related papers. Consider them for comparative context: